
Hanmi’s Q1 earnings hit by China slump but exports up 47% with new hypertension launch on deck
Hanmi Pharmaceutical stumbled in the first quarter of 2025 as weak overseas performance dragged down group earnings, but back home, its core drug business roared back to life. Operating profit dropped 23 percent year-over-year to 59 billion won ($41 …